程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展OA

Human papillomavirus(HPV)infection has become one of the main pathogenic factors of head and neck squamous cell carcinoma(HNSCC).The expression levels of various immune cells and effector molecules,including pro-grammed death(PD)-1 and programmed death-ligand 1,are higher in HPV-positive HNSCC samples than in HPV-nega-tive samples.Furthermore,patients with HPV-positive HNSCC and high PD-1 or PD-L1 expression showed significantly improved survival.Moreover,patients with HPV-positive HNSCC and on anti-PD-1/PD-L1 immunotherapy showed hi-gher objective remission rate(ORR),progression-free survival(PFS),overall survival(OS)and other indicators than pa-tients with HPV-negative HNSCCs,suggesting that the former received greater clinical benefits than the latter.In addi-tion,HPV cancer vaccine combined with PD-1/PD-L1 inhibitors,dual pathway inhibitors and other immunotherapy regi-mens play distinct beneficial roles in HPV-related cancer.Therefore,tailoring immunotherapy to patients based on HPV status is a promising treatment strategy.